Search research articles
Contact Us
Filters
Showing results (101-110 of 181) with videos related to
Page
of 19
Sort By:
Genes
|
January 26, 2021
Characterization of New <i>ATM</i> Deletion Associated with Hereditary Breast Cancer
Sandra Parenti, Claudio Rabacchi, Marco Marino, et al.
Human Mutation
|
January 5, 2026
Characterization of Copy Number Variants in Hereditary Cancer Patients Through NGS Shows a Distinctive PALB2 Contribution to the Diagnostic Yield
Lia Bonamici, Lucia Artuso, Marco Marino, et al.
International Journal of Molecular Sciences
|
June 2, 2021
Detecting Variants in the NBN Gene While Testing for Hereditary Breast Cancer: What to Do Next?
Roberta Zuntini, Elena Bonora, Laura Maria Pradella, et al.
Cancers
|
February 10, 2019
Hereditary Pancreatic Cancer: A Retrospective Single-Center Study of 5143 Italian Families with History of BRCA-Related Malignancies
Angela Toss, Marta Venturelli, Eleonora Molinaro, et al.
Diagnosis (Berlin, Germany)
|
June 18, 2021
Automated capture-based NGS workflow: one thousand patients experience in a clinical routine framework
Elena Tenedini, Fabio Celestini, Pierluigi Iapicca, et al.
Genes
|
April 30, 2021
Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers
Angela Toss, Elena Tenedini, Claudia Piombino, et al.
Current Oncology (Toronto, Ont.)
|
February 26, 2026
Patient Journey for Triple-Negative Breast Cancer: Optimal Care Pathways vs. Reality of Care in Italian Breast Units
Nicla La Verde, Luisa Brogonzoli, Maria Silvia Cona, et al.
Molecular Cancer
|
August 4, 2009
Elongation Factor 1 alpha interacts with phospho-Akt in breast cancer cells and regulates their proliferation, survival and motility
Luisa Pecorari, Oriano Marin, Chiara Silvestri, et al.
Oncotarget
|
February 11, 2017
BRCA1 p.His1673del is a pathogenic mutation associated with a predominant ovarian cancer phenotype
Roberta Zuntini, Laura Cortesi, Daniele Calistri, et al.
The Lancet. Oncology
|
April 30, 2026
CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials
Mohammed S Beshr, Ammar Fahaid, Rana H Shembesh, et al.
Page
of 19
Search research articles
Search
Showing results (101-110 of 181) with videos related to
Sort By:
Page
of 19
Genes
|
January 26, 2021
Characterization of New <i>ATM</i> Deletion Associated with Hereditary Breast Cancer
Sandra Parenti, Claudio Rabacchi, Marco Marino, et al.
Human Mutation
|
January 5, 2026
Characterization of Copy Number Variants in Hereditary Cancer Patients Through NGS Shows a Distinctive PALB2 Contribution to the Diagnostic Yield
Lia Bonamici, Lucia Artuso, Marco Marino, et al.
International Journal of Molecular Sciences
|
June 2, 2021
Detecting Variants in the NBN Gene While Testing for Hereditary Breast Cancer: What to Do Next?
Roberta Zuntini, Elena Bonora, Laura Maria Pradella, et al.
Cancers
|
February 10, 2019
Hereditary Pancreatic Cancer: A Retrospective Single-Center Study of 5143 Italian Families with History of BRCA-Related Malignancies
Angela Toss, Marta Venturelli, Eleonora Molinaro, et al.
Diagnosis (Berlin, Germany)
|
June 18, 2021
Automated capture-based NGS workflow: one thousand patients experience in a clinical routine framework
Elena Tenedini, Fabio Celestini, Pierluigi Iapicca, et al.
Genes
|
April 30, 2021
Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers
Angela Toss, Elena Tenedini, Claudia Piombino, et al.
Current Oncology (Toronto, Ont.)
|
February 26, 2026
Patient Journey for Triple-Negative Breast Cancer: Optimal Care Pathways vs. Reality of Care in Italian Breast Units
Nicla La Verde, Luisa Brogonzoli, Maria Silvia Cona, et al.
Molecular Cancer
|
August 4, 2009
Elongation Factor 1 alpha interacts with phospho-Akt in breast cancer cells and regulates their proliferation, survival and motility
Luisa Pecorari, Oriano Marin, Chiara Silvestri, et al.
Oncotarget
|
February 11, 2017
BRCA1 p.His1673del is a pathogenic mutation associated with a predominant ovarian cancer phenotype
Roberta Zuntini, Laura Cortesi, Daniele Calistri, et al.
The Lancet. Oncology
|
April 30, 2026
CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials
Mohammed S Beshr, Ammar Fahaid, Rana H Shembesh, et al.
Page
of 19